- Cleaner fuel may mean 60-mt loss of demand by 2035: CRISIL report
- IL&FS crisis: What is the Sebi's latest diktat to credit rating agencies?
- Nestle stands to gain the most with Horlicks acquisition, say experts
- Feeling the fuel cost pinch? Here's why petrol should be cheaper by Rs 4
- R&D spend will continue to be around 12% of revenue, says Glenmark CMD
- IHH Healthcare makes open offer for Fortis Malar at Rs 60 per share
- ACME, a firm sitting on the largest solar projects, faces fund crunch
- A few high-growth Indian firms have lion's share in output: World Bank
- Shipping ministry seeks Rs 23.5 billion to fund inland waterway projects
Novartis India Ltd.
|BSE: 500672||Sector: Health care|
|NSE: NOVARTIND||ISIN Code: INE234A01025|
|BSE 00:00 | 20 Nov||690.85||
|NSE 05:30 | 01 Jan||Novartis India Ltd|
|Mkt Cap.(Rs cr)||1,706|
|Mkt Cap.(Rs cr)||1706.40|
Novartis India Ltd. (NOVARTIND) - Latest News & Headlines
9.27 pm | 18 Oct 2018 | Bloomberg
Novartis earlier this year announced the purchase of rare-disease drugmaker AveXis Inc. for $8.7 billion
1.01 pm | 8 Aug 2018 | Business Standard
Novartis India, Merck, GSK Pharma, Pfizer and Sanfoi India have rallied by up to 13% on the BSE in intra-day trade.